Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Aquavit Pharmaceuticals.

    Client Virtual Booth

    AQUAVIT PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Aquavit Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    145 W 57TH ST New York, NY 10019
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aquavitpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aquavit-pharmaceuticals-inc/
    Twitter
    Twitter
    https://twitter.com/aquavitpharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aquavit Files Investigational New Drug Application for its Flagship Intradermal Injection of Botulinum Toxin

    Details:

    Dermatox (botulinum Toxin Type A-aqu) is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for the improvement of skin quality and reduction of fine lines for face and neck.


    Lead Product(s): AqubotulinumtoxinA

    Therapeutic Area: Dermatology Product Name: Dermatox

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 28, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aquavit Files Two IND's For Its Botulinum Toxin With FDA

    Details:

    DTX-023 (botulinum toxin type A) is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for primary axillary hyperhidrosis and palmar hyperhidrosis.


    Lead Product(s): Botulinum toxin type A

    Therapeutic Area: Dermatology Product Name: DTX-023

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 17, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aquavit Files IND with FDA for DTX-021, a New Botulinum Toxin

    Details:

    Dermatox (DTX-021) is a botulinum toxin type A drug, highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum.


    Lead Product(s): Botulinum toxin type A

    Therapeutic Area: Dermatology Product Name: Dermatox

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 24, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aquavit's AQV-1122 COVID-19 Vaccine Patent Approval Fast Tracked by USPTO

    Details:

    Aquavit received a notice of allowance through the USPTO's Fast-Track Prioritized Examination Pilot Program (PEPP) for the application of the company's proprietary technology for self-injectable Covid 19 vaccination (AQV-1122).


    Lead Product(s): AQV-1122

    Therapeutic Area: Infections and Infectious Diseases Product Name: AQV-1122

    Highest Development Status: Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 01, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search